Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

Trends in Immunology

Volumn 29, Issue 5, 2008, Pages 235-241

  Bellone, Matteo ^a   Mondino, Anna ^a   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; CD40 ANTIBODY; CISPLATIN; COMBRETASTATIN A4; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; GEMCITABINE; MELPHALAN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VACCINE; VASCULAR TARGETING AGENT;

ACTIVE IMMUNIZATION; CANCER CHEMOTHERAPY; CELL COMPARTMENTALIZATION; CELL FUNCTION; CLINICAL TRIAL; CYTOTOXICITY; DRUG PENETRATION; ENDOTHELIUM CELL; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOSTIMULATION; NONHUMAN; PROSTATE CANCER; REVIEW; VACCINATION;

ANIMALS; CANCER VACCINES; CAPILLARY PERMEABILITY; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42749085280     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.02.003     Document Type: Review

References (72)

1. Boon T., et al. Human T cell responses against melanoma. Annu. Rev. Immunol. 24 (2006) 175-208
2. Rabinovich G.A., et al. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25 (2007) 267-296
3. Zimmermann V.S., et al. Immune surveillance and anti-tumor immune responses: an anatomical perspective. Immunol. Lett. 98 (2005) 1-8
4. Spiotto M.T., et al. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15 (2003) 725-730
5. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
6. Greenberg N.M., et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3439-3443
7. DeMarzo A.M., et al. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
8. Degl'Innocenti E., et al. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35 (2005) 66-75
9. + regulatory T cells. Cancer Res. 68 (2008) 292-300
10. Drake C.G., et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7 (2005) 239-249
11. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5 (1999) 677-685
12. Zippelius A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64 (2004) 2865-2873
13. Dunn G.P., et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3 (2002) 991-998
14. Henson P.M., and Hume D.A. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 27 (2006) 244-250
15. Bellone M. Apoptosis, cross-presentation, and the fate of the antigen specific immune response. Apoptosis 5 (2000) 307-314
16. Rock K.L., and Kono H. The inflammatory response to cell death. Annu. Rev. Pathol. 3 (2008) 99-126
17. Ronchetti A., et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J. Immunol. 163 (1999) 130-136
18. Castiglioni P., et al. Apoptosis-dependent subversion of the T-lymphocyte epitope hierarchy in lymphoma cells. Cancer Res. 62 (2002) 1116-1122
19. Casares N., et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202 (2005) 1691-1701
20. Miller A.M., and Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol. Immunother. 56 (2007) 81-87
21. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005) 345-352
22. Curiel T.J. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117 (2007) 1167-1174
23. Mellor A.L., and Munn D.H. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8 (2008) 74-80
24. Keir M.E., et al. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 19 (2007) 309-314
25. Rosenberg S.A., et al. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10 (2004) 909-915
26. Bellone M., et al. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165 (2000) 2651-2656
27. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-426
28. Zitvogel L., et al. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8 (2008) 59-73
29. Obeid M., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13 (2007) 54-61
30. Nowak A.K., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170 (2003) 4905-4913
31. Ehrke M.J. Immunomodulation in cancer therapeutics. Int. Immunopharmacol. 3 (2003) 1105-1119
32. Ewens A., et al. Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice. Cancer Res. 66 (2006) 5419-5426
33. +) T cells to the antitumor immune response. J. Exp. Med. 201 (2005) 1591-1602
34. Polak L., and Turk J.L. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249 (1974) 654-656
35. Muranski P., et al. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go?. Nat. Clin. Pract. Oncol. 3 (2006) 668-681
36. Casati A., et al. The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. J. Immunol. 174 (2005) 3317-3325
37. Broomfield S., et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 65 (2005) 7580-7584
38. +) T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13 (2007) 354-360
39. Ko H.-J., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67 (2007) 7477-7486
40. + T cell-directed dendritic cell vaccination. J. Immunol. 179 (2007) 2899-2909
41. McNeel D.G. Prostate cancer immunotherapy. Curr. Opin. Urol. 17 (2007) 175-181
42. Small E.J., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24 (2006) 3089-3094
43. Arlen P.M., et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174 (2005) 539-546
44. Tannock I.F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 20 (2001) 123-132
45. Tredan O., et al. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99 (2007) 1441-1454
46. Minchinton A.I., and Tannock I.F. Drug penetration in solid tumours. Nat. Rev. Cancer 6 (2006) 583-592
47. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271 (1994) 58-65
48. Wijermans P.W., et al. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur. J. Haematol. 50 (1993) 292-296
49. Duda D.G., et al. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J. Clin. Oncol. 25 (2007) 4033-4042
50. Batchelor T.T., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11 (2007) 83-95
51. Taghian A.G., et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J. Clin. Oncol. 23 (2005) 1951-1961
52. Eikenes L., et al. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res. 64 (2004) 4768-4773
53. Brown E., et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat. Med. 9 (2003) 796-800
54. Morinaga Y., et al. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci. 94 (2003) 200-204
55. Hoving S., et al. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res. 65 (2005) 4300-4308
56. Brunstein F., et al. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J. Natl. Cancer Inst. 96 (2004) 1603-1610
57. van der Veen A.H., et al. TNF-α augments intratumoural concentrations of doxorubicin in TNF-α-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer 82 (2000) 973-980
58. Lejeune F.J., et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6 (2006) 6
59. de Wilt J.H., et al. Tumour necrosis factor α increases melphalan concentration in tumour tissue after isolated limb perfusion. Br. J. Cancer 82 (2000) 1000-1003
60. Palladino Jr. M.A., et al. Characterization of the antitumor activities of human tumor necrosis factor-α and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 138 (1987) 4023-4032
61. Eggermont A.M., et al. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 4 (2003) 429-437
62. Curnis F., et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18 (2000) 1185-1190
63. Curnis F., et al. Coupling tumor necrosis factor-α with αV integrin ligands improves its antineoplastic activity. Cancer Res. 64 (2004) 565-571
64. Hajitou A., et al. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc. Med. 16 (2006) 80-88
65. Balza E., et al. Targeted delivery of tumor necrosis factor-α to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin. Cancer Res. 12 (2006) 2575-2582
66. Curnis F., et al. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110 (2002) 475-482
67. Sacchi A., et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin. Cancer Res. 12 (2006) 175-182
68. van Laarhoven H.W., et al. Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas. Invest. New Drugs 24 (2006) 27-36
69. Ruoslahti E. Specialization of tumour vasculature. Nat. Rev. Cancer 2 (2002) 83-90
70. Banchereau J., and Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat. Rev. Immunol. 5 (2005) 296-306
71. Walsh P.C., et al. Clinical practice. Localized prostate cancer. N. Engl. J. Med. 357 (2007) 2696-2705
72. Berthold D.R., et al. Management of advanced prostate cancer after first-line chemotherapy. J. Clin. Oncol. 23 (2005) 8247-8252